Diacomit
Named-patient access overview. Diacomit is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Diacomit (stiripentol) is an antiepileptic medicine approved by the US Food and Drug Administration in 2018 as adjunctive therapy for seizures associated with Dravet syndrome in patients aged 2 years and older taking clobazam. Dravet syndrome is a rare, severe, genetic, treatment-resistant epileptic encephalopathy that typically begins in the first year of life and is most often caused by a pathogenic variant in the SCN1A gene. Diacomit is approximately marketed by Biocodex, a French pharmaceutical company, and it holds long-standing approval in Europe as an orphan medicine.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Diacomit
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Diacomit is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Diacomit in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Diacomit
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.